Our Pricing

Lowest Price 7.5mg Mounjaro UK - From £135.00

Finding the lowest price Mounjaro UK online shouldn't mean compromising on quality or safety. At Cured Pharmacy, we offer genuine UK-licensed Mounjaro (tirzepatide) pens from £135.00, with transparent upfront pricing, free clinical consultations under three minutes, and discreet next-day delivery across the UK. Every prescription is reviewed by our UK-registered clinical team, ensuring you receive safe, effective treatment at the most competitive rates available.

Why Mounjaro Costs Less at Cured Pharmacy

Our pricing model eliminates the hidden consultation fees and subscription traps common at other online pharmacies. At Cured Pharmacy, you see the full cost before completing your clinical assessment—no surprises at checkout. We work directly with UK-licensed wholesalers to secure competitive wholesale rates, then pass those savings directly to patients.

As a fully registered UK pharmacy (GPhC 9012511) under superintendent pharmacist Tarun Kumar (GPhC 2233073), we maintain the same rigorous standards as high-street pharmacies whilst operating with lower overheads. This allows us to offer Mounjaro at rates typically 15-25% below typical market pricing, without compromising on the quality of clinical care or medication authenticity.

Every Mounjaro pen dispensed carries full UK product licensing and batch traceability. We never source from grey-market suppliers or overseas channels, ensuring you receive the same medication your GP would prescribe, simply at a more accessible price point.

How Mounjaro (Tirzepatide) Works for Weight Loss

The 7.5mg dose represents the first maintenance level after initial titration from 2.5mg. Clinical data shows this intermediate dose produces meaningful weight loss whilst minimising gastrointestinal side effects during the adjustment period [1]. Your UK prescriber will determine the appropriate starting dose and escalation schedule based on your individual response and tolerability.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. The injection takes seconds to complete and can be self-administered in the abdomen, thigh, or upper arm. Most patients report minimal injection site discomfort, and the pen's simple design requires no dose calculation or manual preparation.

Dual Receptor Mechanism

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced metabolic effects.

This dual action regulates appetite through central nervous system pathways, slows gastric emptying to prolong satiety, and improves insulin sensitivity. In the pivotal SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 20.9% over 72 weeks—significantly higher than any previous pharmacological obesity treatment [1][2].

Mounjaro vs Other Weight Loss Treatments

Oral weight loss medications like Orlistat work through a completely different mechanism—blocking dietary fat absorption in the intestine rather than regulating appetite hormones. Orlistat typically produces 5-10% weight loss when combined with calorie restriction, making it suitable for patients who prefer tablets or have contraindications to injectable therapies [5].

Your UK prescriber will consider your medical history, previous weight loss attempts, budget constraints, and personal preferences when recommending the most appropriate treatment. All prescription weight loss medications require ongoing lifestyle modifications including reduced calorie intake and increased physical activity for optimal results.

Comparing Injectable GLP-1 Therapies

The UK weight loss injection market now includes several GLP-1 receptor agonists, each with distinct pharmacological profiles. Wegovy (semaglutide) activates only GLP-1 receptors and demonstrated 14.9% average weight loss in the STEP-1 trial over 68 weeks [3]. Saxenda (liraglutide) requires daily injections and typically produces 5-8% body weight reduction over similar timeframes [4].

Head-to-head trials show tirzepatide consistently outperforms semaglutide for weight reduction. The SURPASS-2 study found participants on 15mg tirzepatide lost 5.5kg more on average than those receiving 1mg semaglutide over 40 weeks [2]. However, individual response varies considerably, and some patients achieve excellent results on lower-cost alternatives.

Clinical Evidence: What the Trials Show

The SURMOUNT clinical trial programme represents the most comprehensive investigation of tirzepatide for obesity management to date. SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications, randomising participants to tirzepatide 5mg, 10mg, 15mg, or placebo for 72 weeks [1].

Results showed dose-dependent weight reduction: 15.0% with 5mg, 19.5% with 10mg, and 20.9% with 15mg tirzepatide, compared to 3.1% with placebo. Importantly, 50% of participants on the highest dose achieved at least 20% body weight reduction—a threshold associated with substantial improvements in obesity-related complications including type 2 diabetes, hypertension, and sleep apnoea [1].

The SURMOUNT-2 trial specifically examined tirzepatide in adults with type 2 diabetes and obesity, demonstrating similar weight loss efficacy alongside improved glycaemic control. Average HbA1c reductions of 2.07% were observed with the 15mg dose, with 52% of participants achieving HbA1c <5.7% (non-diabetic range) by week 72 [6].

Safety data across the SURMOUNT programme showed gastrointestinal side effects (nausea, diarrhoea, constipation) as the most common adverse events, typically mild-to-moderate in severity and decreasing over time. Serious adverse events occurred in fewer than 7% of tirzepatide-treated participants, comparable to placebo rates [1][6].

Who Can Use Mounjaro: Eligibility Criteria

Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should be used with caution in individuals with severe gastrointestinal disease, history of pancreatitis, or severe renal impairment [7].

During your online consultation at Cured Pharmacy, our UK prescribers will review your complete medical history, current medications, and previous weight loss attempts. This assessment typically takes under three minutes to complete and ensures Mounjaro is both safe and appropriate for your specific situation. If our clinical team identifies any contraindications, they will recommend alternative treatments better suited to your needs.

MHRA-Approved Indications

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or BMI 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [7]. The medication must be prescribed alongside a reduced-calorie diet and increased physical activity.

NICE guidance recommends considering GLP-1 receptor agonists for weight management when lifestyle interventions alone have proven insufficient and the patient demonstrates commitment to long-term treatment [8]. Your UK prescriber will assess whether Mounjaro represents the most clinically appropriate option based on your individual circumstances.

Starting Mounjaro: What to Expect

Most patients notice reduced appetite within the first week of treatment, though measurable weight loss typically becomes apparent after 4-8 weeks. Maximum weight loss generally occurs between 60-72 weeks of continuous treatment, with weight stabilisation thereafter [1].

Common initial side effects include mild nausea, occasional vomiting, and changes in bowel habits. These effects usually diminish within 4-8 weeks as your body adapts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise gastrointestinal discomfort during the adjustment period.

At Cured Pharmacy, we provide comprehensive patient information leaflets with every Mounjaro prescription, including injection technique videos, side effect management strategies, and 24/7 access to our clinical support team. Our pharmacists remain available throughout your treatment journey to address any questions or concerns that arise.

Dosing Schedule and Titration

All patients begin Mounjaro at 2.5mg once weekly for the first four weeks. This initial dose allows your body to adjust to the medication whilst minimising gastrointestinal side effects. After four weeks, the dose escalates to 5mg weekly, then potentially to 7.5mg, 10mg, 12.5mg, or 15mg at four-week intervals based on your weight loss response and tolerability [7].

The 7.5mg dose featured in our pricing represents the third titration step and the first maintenance level many patients remain on long-term. Clinical trials show substantial weight loss occurs at this dose whilst side effects remain manageable for most individuals [1]. Your prescriber will determine the optimal maintenance dose during follow-up consultations.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
6. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
7. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/14443/smpc
8. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. Retrieved from https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to reduced-calorie diet and increased physical activity alongside medication. Mounjaro is a registered trademark of Eli Lilly and Company.